Minerva Neurosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting a net income of $100,746,561 for the third quarter driven primarily by a change in fair value of its warrant liability.

Key Highlights

  • Q3 2026 net income: $100,746,561, compared to a net loss of $2,743,954 in Q3 2025, according to the filing.
  • Warrant liability fair value change: The company recorded a $109,601,827 gain from changes in fair value of the warrant liability in Q3 2026, the primary driver of reported net income.
  • Nine-month net loss: For the nine months ended September 30, 2026, the company reported a net loss of $7,191,538, compared to a net loss of $9,755,514 for the same period in 2025.
  • Total expenses increased sharply: Total operating expenses for the nine months ended September 30, 2026, were $36,747,388, up from $10,121,381 for the same period in 2025.
  • Cash and marketable securities: Cash and cash equivalents stood at $20,216,241 and marketable securities at $56,728,533 as of September 30, 2026, versus $82,301,813 in cash and no marketable securities as of December 31, 2025.
  • Shares outstanding: 49,835,241 shares of common stock were outstanding as of November 3, 2026, up from 43,274,398 as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $695,991,278 as of September 30, 2026, compared to $688,799,740 as of December 31, 2025.

Minerva Neurosciences Q3 2026 Financial Results: Warrant Liability Drives Headline Income

According to the filing, Minerva Neurosciences (NASDAQ:NERV) reported Q3 2026 net income of $100,746,561, a significant reversal from the net loss of $2,743,954 recorded in Q3 2025. The company disclosed that this result was driven primarily by a $109,601,827 gain from changes in fair value of its warrant liability, which stood at $121,534,829 on the balance sheet as of September 30, 2026, down from $171,464,575 as of December 31, 2025. The filing noted that net income attributable to common stockholders was $95,662,099 for Q3 2026, after subtracting $5,084,462 in undistributed earnings attributable to participating preferred stock.

On an operating basis, the company reported a loss from operations of $9,433,677 for Q3 2026, compared to $2,844,348 for Q3 2025. Research and development expenses rose to $5,155,658 in Q3 2026 from $925,377 in Q3 2025, and general and administrative expenses increased to $4,278,019 from $1,918,971 over the same periods, the filing stated. For the nine months ended September 30, 2026, total expenses reached $36,747,388, compared to $10,121,381 for the same period in 2025.

The balance sheet reflected total assets of $98,278,196 as of September 30, 2026, against total liabilities of $184,060,770, resulting in a total stockholders' deficit of $97,523,878, an improvement from the $140,748,082 deficit reported as of December 31, 2025. The company also reported a liability related to the sale of future royalties of $60,000,000, unchanged from December 31, 2025. The filing contains forward-looking statements that the company identifies as subject to risks and uncertainties described in its Risk Factors disclosures.

What Was Disclosed

Minerva Neurosciences filed its quarterly report for the period ended September 30, 2026, disclosing Q3 2026 net income of $100,746,561 primarily from a warrant liability fair value gain, alongside an operating loss of $9,433,677 and a nine-month net loss of $7,191,538.